Figure 2.

OS after progression with osimertinib. Kaplan-Meier curves estimating the OS according to progression patterns (A), patients’ conditions (B), continuation or discontinuation of osimertinib in clinically stable patients (C), continuation or discontinuation of osimertinib in clinically stable patients with CNS metastasis only progression (D), continuation or discontinuation of osimertinib in clinically stable patients with oligoprogression (E) and continuation or discontinuation of osimertinib in clinically stable patients with multiple organs progression (F). OS was determined starting from the date of progression with osimertinib. CI, confidence interval; CNS, central nervous system; HR, hazard ratio; OS, overall survival; PD, progressive disease. RECIST, Response Evaluation Criteria in Solid Tumors.